- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Vaxart Inc (VXRT)
Vaxart Inc stock price live, this page displays OTC VXRT stock exchange data. View the VXRT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Vaxart Inc real time stock price chart below.
What Is the Vaxart Inc Stock Price Today?
The Vaxart Inc stock price today is 0.5598.
What Is the Stock Symbol for Vaxart Inc?
The stock symbol for Vaxart Inc is "VXRT."
What Stock Exchange Does Vaxart Inc Trade On?
Vaxart Inc is listed and trades on the OTC Markets stock exchange.
Is Vaxart Inc a Good Stock to Buy?
Determining whether Vaxart Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VXRT quote. (ISIN: US92243A2006)
What Is the Vaxart Inc Stock Price Today?
The Vaxart Inc stock price today is 0.5598.
What Is the Stock Symbol for Vaxart Inc?
The stock symbol for Vaxart Inc is "VXRT."
What Stock Exchange Does Vaxart Inc Trade On?
Vaxart Inc is listed and trades on the OTC Markets stock exchange.
Is Vaxart Inc a Good Stock to Buy?
Determining whether Vaxart Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VXRT quote. (ISIN: US92243A2006)
0.5598
+0.0025(+0.45%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.5351
0.5725
52 wk Range
0.3050
0.8449
VXRT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.53510.5725
52 wk Range
0.30500.8449
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VXRT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
3.3333
Upside
+495.45%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
Form 4 Vaxart Inc For: 21 July- Investing.com
- Form 4 Vaxart Inc For: 21 July
- Investing.com
Form 4 Vaxart Inc For: 17 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 3.3333
(+495.45% Upside)
Vaxart Inc Earnings Call Summary for Q2/2026
- Vaxart missed Q2 2026 estimates with revenue of $27.2M (down 46% vs. forecast) and a 6-cent loss per share versus 3-cent expected loss.
- Revenue fell 31.5% YoY due to lower BARDA contract revenue; R&D spending dropped 32.2%, narrowing net loss to $13.5M from $15M prior year.
- Company holds $64M cash with runway into Q2 2027; BARDA released additional $29M for expanded COVID-19 trial analysis and completion.
- Main COVID-19 trial (5,000 participants) fully enrolled; top-line efficacy and safety data expected in first half of 2027 per management guidance.
- Shares fell 3.4% to $0.55; company pursuing non-dilutive funding including government contracts, partnerships, and $25M Lincoln Park facility.
Last Updated: 08/08/2026, 05:28 AM
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.06 / -0.03
Revenue / Forecast
27.19M / 50.5M
Compare VXRT to Peers and Sector
Metrics to compare | VXRT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVXRTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.5x | −1.7x | −0.3x | |
PEG Ratio | 0.02 | −0.13 | 0.00 | |
Price/Book | 1.7x | 2.0x | 2.6x | |
Price / LTM Sales | 0.6x | 133.4x | 3.1x | |
Upside (Analyst Target) | - | 480.2% | 48.3% | |
Fair Value Upside | Unlock | 7.4% | 6.7% | Unlock |
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII; COVID-19 Vaccine, which is in Phase 2b clinical trial for the treatment of SARS-CoV-1, SARS-CoV-2, and Middle East respiratory syndrome coronavirus; Seasonal Influenza vaccine, which is in Phase 2 clinical trial, to treat H1N1 Influenza; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. The company also provides VAAST (Vector-Adjuvant-Antigen Standardized Technology) Platform, a unique modular vaccine platform. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Vaxart (VXRT) Stock Price Today?
The Vaxart stock price today is 0.5598 USD.
What Stock Exchange Does Vaxart Trade On?
Vaxart is listed and trades on the OTC Markets.
What Is the Stock Symbol for Vaxart?
The stock symbol for Vaxart is "VXRT."
What Is the Vaxart Market Cap?
As of today, Vaxart market cap is 135.9400M USD.
What Is Vaxart's Earnings Per Share (TTM)?
The Vaxart EPS (TTM) is 0.1620.
When Is the Next Vaxart Earnings Date?
Vaxart will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is VXRT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Vaxart Stock Split?
Vaxart has split 2 times.
How Many Employees Does Vaxart Have?
Vaxart has 65 employees.
What is the current trading status of Vaxart (VXRT)?
As of Aug 13, 2026, Vaxart (VXRT) is trading at a price of 0.5598 USD, with a previous close of 0.5573 USD. The stock has fluctuated within a day range of 0.5351 USD to 0.5725 USD, while its 52-week range spans from 0.3050 USD to 0.8449 USD.
What Is Vaxart (VXRT) Price Target According to Analysts?
The average 12-month price target for Vaxart is 3.3333 USD, with a high estimate of 4 USD and a low estimate of 2 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +495.45% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.